Nilotinib Viatris

Nilotinib, the active ingredient in Nilotinib Viatris, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia in adult patients. GNH USA supplies Nilotinib Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nilotinib is a tyrosine kinase inhibitor used in the management of chronic myeloid leukemia (CML).

- Chronic myeloid leukemia (chronic phase): Achieves cytogenetic and molecular remission in adult patients with Philadelphia chromosome‑positive disease. - Chronic myeloid leukemia (accelerated phase): Helps control disease progression and improve survival. - Chronic myeloid leukemia (blast phase): Used as part of combination therapy to reduce leukemic blast burden.

Common side effects are typically mild to moderate and may resolve with continued therapy.

Common Side Effects: - Nausea - Diarrhea - Fatigue - Rash - Muscle cramps - Elevated lipase

Serious or Rare Side Effects: - QT interval prolongation - Severe hepatotoxicity - Acute pancreatitis - Severe neutropenia or thrombocytopenia

Nilotinib requires careful monitoring and patient education to minimize risks.

- Monitor blood counts: Perform regular CBC to detect cytopenias. - Assess cardiac function: Watch for QT prolongation and correct electrolyte abnormalities. - Check liver enzymes: Monitor hepatic function periodically. - Avoid strong CYP3A4 inhibitors: They can increase nilotinib exposure. - Store at ambient temperature: Keep below 25°C, protect from moisture and keep in the original packaging.

Nilotinib interacts with several drug classes; some combinations should be avoided while others need close observation.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): May raise nilotinib plasma levels. - QT‑prolonging agents (e.g., amiodarone, fluoroquinolones): Increase risk of cardiac arrhythmias. - Antacids containing aluminum or magnesium: Reduce nilotinib absorption.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): May lower nilotinib exposure. - Warfarin: Potential alteration of INR, requiring dose adjustment. - Statins such as simvastatin: Heightened risk of myopathy, consider alternative lipid‑lowering therapy.